`U.S. Patent 10,335,462
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`______________________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`______________________
`
`MYLAN PHARMACEUTICALS, INC.,
`Petitioner
`
`v.
`
`NOVO NORDISK A/S,
`Patent Owner
`______________________
`Case IPR2023-00724
`Patent 10,335,462
`______________________
`
`DECLARATION OF JENNY C. WU IN SUPPORT OF
`PATENT OWNER’S UNOPPOSED MOTION FOR
`PRO HAC VICE ADMISSION
`
`1
`
`Novo Nordisk Exhibit 2535
`Mylan Pharms. Inc. v. Novo Nordisk A/S
`IPR2023-00724
`Page 00001
`
`
`
`IPR2023-00724
`U.S. Patent 10,335,462
`
`Pursuant to 37 C.F.R. § 1.68, I, Jenny C. Wu, declare as follows:
`
`1.
`
`I am a member in good standing of the New York Bar. I am admitted to
`
`practice before the United States District Court for the Southern District of New
`
`York, the United States District Court for the Eastern District of New York, the
`
`United States District Court for the Eastern District of Michigan, the United States
`
`District Court for the Western District of Wisconsin, and the United States Court
`
`of Appeals for the Federal Circuit. I have personal knowledge of the facts set forth
`
`in this Declaration. All statements herein made of my own knowledge are true and
`
`all statements made on information and belief are believed to be true.
`
`2.
`
`I have never been suspended or disbarred from practice before any court or
`
`administrative body.
`
`3.
`
`I have never had any application for admission to practice before any court
`
`or administrative body ever denied.
`
`4.
`
`I have never had any sanctions or contempt citations imposed against me
`
`by any court or administrative body.
`
`5.
`
`I have read and will comply with the Patent Trial and Appeal Board
`
`Consolidated Trial Practice Guide and the Board’s Rules for Practice for Trials
`
`set forth in part 42 of title 37 of the Code of Federal Regulations.
`
`2
`
`Novo Nordisk Exhibit 2535
`Mylan Pharms. Inc. v. Novo Nordisk A/S
`IPR2023-00724
`Page 00002
`
`
`
`IPR2023-00724
`U.S. Patent 10,335,462
`
`6.
`
`I agree to be subject to the USPTO Rules of Professional Conduct set forth
`
`in 37 C.F.R. §§ 11.101 et seq., and to disciplinary jurisdiction under 37 C.F.R.
`
`§ 11.19(a).
`
`7.
`
`In the last three years, I have applied and have been granted to appear
`
`pro hac vice in IPR2021-01398, IPR2021-01430, and IPR2021-01458
`
`proceedings before the United States Patent and Trademark Office.
`
`8.
`
`I have an established familiarity with U.S. Patent No. 10,335,462 (the
`
`“’462 Patent”), the patented technology, and the specific subject matter in this
`
`proceeding. Since April 2023, I have been heavily involved with this
`
`proceeding, including in the analysis of the claim construction and invalidity
`
`issues raised by Mylan. I have substantively participated in the analysis of the
`
`Petition, preparation of the Patent Owner’s Preliminary Response, analysis of
`
`the Institution Decision, and Preparation of Patent Owner’s Response, and am
`
`thus familiar with the filings and various issues raised in this proceeding.
`
`9.
`
`I am an experienced litigation attorney and have been practicing law for
`
`over 10 years. During this time, I have litigated numerous patent infringement
`
`cases at all stages in many different District Courts across the country. I have
`
`been part of multiple trials, Markman hearings, patent summary judgment
`
`proceedings, patent appeals at the United States Court of Appeals for the Federal
`
`3
`
`Novo Nordisk Exhibit 2535
`Mylan Pharms. Inc. v. Novo Nordisk A/S
`IPR2023-00724
`Page 00003
`
`
`
`IPR2023-00724
`U.S. Patent 10,335,462
`
`Circuit, and other patent-related hearings and pleadings concerning, inter alia,
`
`patent validity and infringement issues.
`
`10.
`
`I have been warned that willful false statements and the like are punishable
`
`by fine or imprisonment, or both (18 U.S.C. 1001) and may jeopardize the validity
`
`of the patent at issue in this proceeding.
`
`I declare under penalty of perjury that the foregoing is true and correct.
`
`Dated: March 6, 2024
`
`/Jenny Wu /
`Jenny C. Wu
`
`4
`
`Novo Nordisk Exhibit 2535
`Mylan Pharms. Inc. v. Novo Nordisk A/S
`IPR2023-00724
`Page 00004
`
`
Accessing this document will incur an additional charge of $.
After purchase, you can access this document again without charge.
Accept $ Charge
Still Working On It
This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.
Give it another minute or two to complete, and then try the refresh button.
A few More Minutes ... Still Working
It can take up to 5 minutes for us to download a document if the court servers are running slowly.
Thank you for your continued patience.
This document could not be displayed.
We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.
Your account does not support viewing this document.
You need a Paid Account to view this document. Click here to change your account type.
Your account does not support viewing this document.
Set your membership
status to view this document.
With a Docket Alarm membership, you'll
get a whole lot more, including:
- Up-to-date information for this case.
- Email alerts whenever there is an update.
- Full text search for other cases.
- Get email alerts whenever a new case matches your search.
One Moment Please
The filing “” is large (MB) and is being downloaded.
Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.
Your document is on its way!
If you do not receive the document in five minutes, contact support at support@docketalarm.com.
Sealed Document
We are unable to display this document, it may be under a court ordered seal.
If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.
Access Government Site
